AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26164621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group family‐based cognitive behavioural therapy (CBT)
Number of subjects: 842
Study 24503744 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 24503744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial still point induction
Number of subjects: 0
Study 22272780 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally- and gender-relevant asthma-management intervention delivered over the telephone
Number of subjects: 420
Study 22272780 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 420
Study 19343318 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroverine (80 mg)
Number of subjects: 10
Study 19343318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15886217 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous haemodiafiltration (CVVHDF)
Number of subjects: 125
Study 15886217 — intervention group
Group type: COMPARATOR
Intervention: Intermittent haemodialysis (IHD)
Number of subjects: 125
Study 12645718 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.03 U/min)
Number of subjects: 27
Study 11057406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderma injection of Tc‐99m nanocolloid
Number of subjects: 45
Study 11057406 — intervention group
Group type: COMPARATOR
Intervention: Peritumoural injection of Tc‐99m nanocolloid
Number of subjects: 45
Study 11057406 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both injection methods
Number of subjects: 45
Study 11057406 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritumoural injection
Number of subjects: 45
Study 8790025 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.1 mg/kg bolus followed by infusion of 0.1 mg/kg per hour)
Number of subjects: 3002
Study 8790025 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 U bolus followed by infusion of 1000 U/h)
Number of subjects: 3002
Study 8790025 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 3002
Study 8790025 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3002
Study 1535215 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin
Number of subjects: 20
Study 1535215 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide
Number of subjects: 20
Study 1535215 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of erythromycin and benzoyl peroxide
Number of subjects: 20
Study 6439233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 288
Study 6439233 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 288
Study 6439233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 6439233 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 288
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA)
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys vs Girls in LPA
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys vs Girls in MVPA
Number of subjects: 600
Study 30509928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index and BMI z scores
Number of subjects: 600
Study 28152465 — intervention group
Group type: EXPERIMENTAL
Intervention: MET plus oxytocin
Number of subjects: 16
Study 28152465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25393172 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with financial incentives for abstinence; 4 weeks duration
Number of subjects: 146
Study 25393172 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; cessation program)
Number of subjects: 146
Study 24613024 — intervention group
Group type: EXPERIMENTAL
Intervention: Solomon technique (fetoscopic laser coagulation of the entire vascular equator)
Number of subjects: 274
Study 24613024 — intervention group
Group type: COMPARATOR
Intervention: Standard laser coagulation
Number of subjects: 274
Study 24613024 — intervention group
Group type: EXPERIMENTAL
Intervention: Solomon technique
Number of subjects: 274
Study 22443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive microfinance intervention (matched savings accounts, financial management workshops, mentorship)
Number of subjects: 286
Study 22443837 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional services: counseling and school supplies)
Number of subjects: 286
Study 19923168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180‐mg load, 90‐mg BID maintenance dose)
Number of subjects: 123
Study 19923168 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600‐mg load, 75‐mg/d maintenance dose)
Number of subjects: 123
Study 17876889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intermittent interferon (IFN) therapy (3 MIU of natural IFN‐alpha intramuscularly 3 times weekly for at least 48 weeks)
Number of subjects: 32
Study 17876889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intermittent interferon (IFN) therapy
Number of subjects: 32
Study 17876889 — intervention group
Group type: COMPARATOR
Intervention: Non-IFN group (historical controls)
Number of subjects: 32
Study 16009829 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost therapy alone
Number of subjects: 37
Study 16009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost-timolol-fixed combination therapy
Number of subjects: 37
Study 12774194 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 micro g p.o. b.i.d. for 14 days)
Number of subjects: 10
Study 11307189 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation group (10 subjects) with clockwise rotation of the palatal plane
Number of subjects: 23
Study 11307189 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaction group (13 subjects) with maxillary superior repositioning
Number of subjects: 23
Study 11307189 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 adults) with skeletal Class III malocclusion without open bite
Number of subjects: 23
Study 8966497 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50 mikrog/day
Number of subjects: 32
Study 8966497 — intervention group
Group type: COMPARATOR
Intervention: Premarin 0.625 mg
Number of subjects: 32
Study 8966497 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50 mikrog/day and Premarin 0.625 mg
Number of subjects: 32
Study 1563807 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 10 mg/kg/day for four courses of 30 days with 15‐day drug‐free intervals
Number of subjects: 25
Study 1563807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 50‐70 mg/kg/day continuously for between 6 and 24 months
Number of subjects: 25
Study 6386490 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐38,485 50 mg
Number of subjects: 10
Study 6386490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31208943 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation TKIs
Number of subjects: 0
Study 31208943 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 31208943 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation TKIs (favourable scenarios)
Number of subjects: 0
Study 31208943 — intervention group
Group type: COMPARATOR
Intervention: Second-generation TKIs vs Imatinib
Number of subjects: 0
Study 28753851 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 (1200-1800mg/d)
Number of subjects: 41
Study 27282110 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft (gracilis and semitendinosus tendons)
Number of subjects: 90
Study 27282110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid graft (γ‐irradiated tibialis anterior tendon allograft and semitendinosus tendon autograft)
Number of subjects: 90
Study 27282110 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐irradiated allograft (tibialis anterior tendons)
Number of subjects: 90
Study 27282110 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 24666811 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity, group aerobic exercise intervention (AE)
Number of subjects: 48
Study 24666811 — intervention group
Group type: COMPARATOR
Intervention: Brief advice to exercise intervention (BA-E)
Number of subjects: 48
Study 22673453 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised aerobic training (50 min, 4 times per week)
Number of subjects: 176
Study 22673453 — intervention group
Group type: COMPARATOR
Intervention: Control group (attended lectures on physical activity and health once a month)
Number of subjects: 176
Study 20218940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural analgesia and general anesthesia (group EA/GA)
Number of subjects: 40
Study 20218940 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (group GA)
Number of subjects: 40
Study 16905139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lovastatin
Number of subjects: 1351
Study 16905139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lovastatin
Number of subjects: 1351
Study 16905139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 1351
Study 16905139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1351
Study 16905139 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effects (lovastatin and warfarin vs placebo)
Number of subjects: 1351
Study 17315548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic fentanyl (TTS‐F) patches releasing 25 microg fentanyl per hour
Number of subjects: 460
Study 17315548 — intervention group
Group type: COMPARATOR
Intervention: Codeine/paracetamol (120 mg per day)
Number of subjects: 460
Study 12354129 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution (0.17 mg GH/day, titrated every 6-8 weeks)
Number of subjects: 18
Study 12354129 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution (0.17 mg GH/day, titrated to T(max) and then reduced to T(end))
Number of subjects: 18
Study 12354129 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution
Number of subjects: 18
Study 12354129 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 matched control subjects)
Number of subjects: 18
Study 9973032 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing stress echocardiography
Number of subjects: 104
Study 9973032 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stress echocardiography
Number of subjects: 104
Study 9973032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 104
Study 7569485 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric inpatient assessment and rehabilitation
Number of subjects: 312
Study 7569485 — intervention group
Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 312
Study 2299950 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt dissection tonsillectomy using suture ligatures for hemostasis, without postoperative antibiotics
Number of subjects: 80
Study 2299950 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery, dissection, KTP laser
Number of subjects: 80
Study 2299950 — intervention group
Group type: COMPARATOR
Intervention: Methods of hemostasis (electrocautery, suture ligature)
Number of subjects: 80
Study 2299950 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 80
Study 6109150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY), 100 mg a day and Aspirin (ASA), 1200 mg a day
Number of subjects: 38
Study 6109150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6109150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY) and Aspirin (ASA)
Number of subjects: 38
Study 29778340 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIPFIX sternal closure system
Number of subjects: 118
Study 29778340 — intervention group
Group type: COMPARATOR
Intervention: Standard stainless steel wires
Number of subjects: 118
Study 23475825 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR-methylphenidate)
Number of subjects: 63
Study 23475825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 63
Study 26205958 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Program (HeLP‐her Rural) with multiple delivery modes (group sessions, phone coaching, text messages, interactive program manual)
Number of subjects: 649
Study 26205958 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group sessions
Number of subjects: 649
Study 26205958 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages and phone coaching
Number of subjects: 649
Study 26205958 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lifestyle advice via multiple delivery modes
Number of subjects: 649
Study 23036139 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic and nutritional supplements (NNS)
Number of subjects: 134
Study 23036139 — intervention group
Group type: COMPARATOR
Intervention: No Naturopathic and nutritional supplements (NNS)
Number of subjects: 134
Study 20584236 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (SFP) 10-14
Number of subjects: 57
Study 20584236 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 57
Study 19173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lamivudine and traditional Chinese medicine
Number of subjects: 0
Study 19173973 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 0
Study 15857327 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 27
Study 15857327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 27
Study 14594786 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread A (25 g/d containing 43 mg alpha‐TE and 0.45 mg carotenoids)
Number of subjects: 105
Study 14594786 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread B (25 g/d containing 111 mg alpha‐TE and 1.24 mg carotenoids)
Number of subjects: 105
Study 14594786 — intervention group
Group type: COMPARATOR
Intervention: Spread C (25 g/d containing 1.3 mg RRR‐alpha‐tocopherol without carotenoids)
Number of subjects: 105
Study 10847255 — intervention group
Group type: COMPARATOR
Intervention: Leisure time physical activity (groups 2 to 4)
Number of subjects: 30640
Study 10847255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports participation
Number of subjects: 30640
Study 10847255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling to work
Number of subjects: 30640
Study 8853832 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg oral dose
Number of subjects: 9
Study 8853832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1633756 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-specific acupuncture
Number of subjects: 56
Study 1633756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham transdermal stimulation
Number of subjects: 56
Study 1633756 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 56
Study 6392119 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamid (40 mg)
Number of subjects: 17
Study 6392119 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (50 mg)
Number of subjects: 17
Study 6392119 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamid (80 mg)
Number of subjects: 17
Study 6392119 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (100 mg)
Number of subjects: 17
Study 6392119 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 31525156 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive thinking training (10 sessions of 45-60 minutes over 5 weeks)
Number of subjects: 52
Study 31525156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 31525156 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive thinking training
Number of subjects: 52
Study 29764262 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 (20% IgG stabilized with L‐Proline)
Number of subjects: 172
Study 29764262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29764262 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous method
Number of subjects: 172
Study 29764262 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIG
Number of subjects: 172
Study 26901268 — intervention group
Group type: EXPERIMENTAL
Intervention: The Coach Approach exercise‐support protocol followed by group nutrition sessions
Number of subjects: 110
Study 26901268 — intervention group
Group type: COMPARATOR
Intervention: Comparison treatment with a print manual plus telephone follow‐ups
Number of subjects: 110
Study 24722497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Mediterranean Diet (LCMD)
Number of subjects: 215
Study 24722497 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 215
Study 22666496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 1065
Study 22666496 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 1065
Study 20863918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 146
Study 20863918 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 146
Study 20863918 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with AR
Number of subjects: 146
Study 18508833 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive C-reactive protein (CRP) measurements on admission, day 3, and day 7 during follow-up of antibiotic treatment.
Number of subjects: 289
Study 15889132 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy for 1 to 72 hours
Number of subjects: 0
Study 15889132 — intervention group
Group type: COMPARATOR
Intervention: Greater than 80% oxygen for more than 6 hours
Number of subjects: 0
Study 15889132 — intervention group
Group type: COMPARATOR
Intervention: Room air controls
Number of subjects: 0
Study 12824997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal fibronectin test results known to physician
Number of subjects: 108
Study 12824997 — intervention group
Group type: COMPARATOR
Intervention: Fetal fibronectin test results not known to physician
Number of subjects: 108
Study 11722049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suture technique
Number of subjects: 300
Study 11722049 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous suture technique
Number of subjects: 300
Study 9202910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg intravenous (i.v.)
Number of subjects: 256
Study 9202910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 7960608 — intervention group
Group type: EXPERIMENTAL
Intervention: E (epirubicin) alone (90 mg/m2 day 1)
Number of subjects: 165
Study 7960608 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU (5-Fluorouracil) alone (500 mg/m2 days 1‐5)
Number of subjects: 165
Study 7960608 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU (400 mg/m2 days 1‐5) plus E (epirubicin) (90 mg/m2 day 1)
Number of subjects: 165
Study 7960608 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study 3659830 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with Hemoccult‐II
Number of subjects: 60938
Study 3659830 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60938
Study 30334066 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cone beam CTs (CBCT)
Number of subjects: 23
Study 25769614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h)
Number of subjects: 80
Study 25769614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23884915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral T4 (2 μg·kg⁻¹)
Number of subjects: 32
Study 23884915 — intervention group
Group type: COMPARATOR
Intervention: Intravenous T4 (2 μg·kg⁻¹)
Number of subjects: 32
Study 23884915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral T4
Number of subjects: 32
Study 23884915 — intervention group
Group type: COMPARATOR
Intervention: Intravenous T4
Number of subjects: 32
Study 22043670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (Back‐shu points of Five‐zang and Geshu (BL 17), Taichong (LR 3), Sanyinjiao (SP 6), Shenmen (HT 7))
Number of subjects: 60
Study 22043670 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (Fluoxetine Hydrochloride capsule, 20 mg, once a day)
Number of subjects: 60
Study 19171813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 19171813 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 17002927 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 24
Study 17002927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15304961 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of potassium iodide (38 mg of iodide)
Number of subjects: 8
Study 15304961 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of potassium iodide (76 mg of iodide)
Number of subjects: 8
Study 10807748 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype
Number of subjects: 586
Study 10807748 — intervention group
Group type: COMPARATOR
Intervention: GT+GG genotypes
Number of subjects: 586